A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Recruiting · Phase 1 · NCT07061288
Conditions: Schizophrenia
At a glance
- Research payments reported, 2025
- $46,977
- U.S. investigators named
- 6
- Sites paid
- 5
- Planned or actual enrollment
- 131
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- KarXT (drug)
- Dates
- Started 2025-09-03; completion 2027-10-15
- Results posted
- Not yet
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $46,977 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Edwin A. Gomez, M.D. Psychiatry · Weston, FL
- Rishi Kakar, M.D. Psychiatry · Tamarac, FL
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Kimberly L. Johnson, M.D. Anesthesiology · Chicago, IL
- Elyssa L. Barron, M.D. Psychiatry · White Plains, NY
- David W. Brown, M.D. Psychiatry · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Research Centers of America $26,175
- Cenexel Atlanta $11,852
- Cenexel Iresearch, Llc $4,641
- Miami Lakes Medical Research $3,059
- Community Clinical Research $1,251
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.